CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev therapy. T...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Med
Prif Awduron: Nishikawa, Masahiro, Inoue, Akihiro, Ohnishi, Takanori, Yano, Hajime, Kanemura, Yonehiro, Kohno, Shohei, Ohue, Shiro, Ozaki, Saya, Matsumoto, Shirabe, Suehiro, Satoshi, Nakamura, Yawara, Shigekawa, Seiji, Watanabe, Hideaki, Kitazawa, Riko, Tanaka, Junya, Kunieda, Takeharu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2021
Pynciau:
Clinical Cancer Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7957167/
https://ncbi.nlm.nih.gov/pubmed/33543833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3767
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg